AU2001290143A1 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases - Google Patents

Morpholin-acetamide derivatives for the treatment of inflammatory diseases

Info

Publication number
AU2001290143A1
AU2001290143A1 AU2001290143A AU9014301A AU2001290143A1 AU 2001290143 A1 AU2001290143 A1 AU 2001290143A1 AU 2001290143 A AU2001290143 A AU 2001290143A AU 9014301 A AU9014301 A AU 9014301A AU 2001290143 A1 AU2001290143 A1 AU 2001290143A1
Authority
AU
Australia
Prior art keywords
heteroaryl
formula
alkyl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290143A
Other languages
English (en)
Inventor
Rachael Anne Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Graeme Michael Robertson
Stephen Swanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023902A external-priority patent/GB0023902D0/en
Priority claimed from GB0107644A external-priority patent/GB0107644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001290143A1 publication Critical patent/AU2001290143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
AU2001290143A 2000-09-29 2001-09-28 Morpholin-acetamide derivatives for the treatment of inflammatory diseases Abandoned AU2001290143A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023902A GB0023902D0 (en) 2000-09-29 2000-09-29 Therapeutically useful compounds
GB0023902 2000-09-29
GB0107644A GB0107644D0 (en) 2001-03-27 2001-03-27 Therapeutically useful compounds
GB0107644 2001-03-27
PCT/GB2001/004345 WO2002026722A1 (fr) 2000-09-29 2001-09-28 Derives de morpholine-acetamide permettant de traiter les maladies inflammatoires

Publications (1)

Publication Number Publication Date
AU2001290143A1 true AU2001290143A1 (en) 2002-04-08

Family

ID=26245078

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290143A Abandoned AU2001290143A1 (en) 2000-09-29 2001-09-28 Morpholin-acetamide derivatives for the treatment of inflammatory diseases

Country Status (18)

Country Link
US (4) US7101882B2 (fr)
EP (1) EP1324990B1 (fr)
JP (1) JP5089846B2 (fr)
KR (1) KR20030031198A (fr)
CN (1) CN1678594A (fr)
AR (1) AR035205A1 (fr)
AU (1) AU2001290143A1 (fr)
BR (1) BR0114323A (fr)
CA (1) CA2423251A1 (fr)
CZ (1) CZ20031195A3 (fr)
ES (1) ES2527688T3 (fr)
HU (1) HUP0302302A2 (fr)
IL (1) IL155093A0 (fr)
MX (1) MXPA03002814A (fr)
NO (1) NO20031442L (fr)
NZ (1) NZ525056A (fr)
PL (1) PL362711A1 (fr)
WO (1) WO2002026722A1 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030031198A (ko) * 2000-09-29 2003-04-18 글락소 그룹 리미티드 염증 질환 치료용 모르폴린-아세트아미드 유도체
DE60108420T2 (de) * 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
GB0208158D0 (en) * 2002-03-28 2002-05-22 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207443D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207449D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207445D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0211759D0 (en) * 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB0212355D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1801108B9 (fr) * 2004-09-08 2013-11-20 Mitsubishi Tanabe Pharma Corporation Composes de morpholine pour le traitement des inflammations
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20090118288A1 (en) * 2005-07-21 2009-05-07 Astrazeneca Ab N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor
BRPI0710240A2 (pt) 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
MX2009002019A (es) 2006-08-24 2009-03-09 Novartis Ag Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
BRPI0718509A2 (pt) 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
AU2007336238A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as SCD inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
KR20160129109A (ko) 2008-05-23 2016-11-08 아미라 파마슈티칼스 인코포레이티드 5-리폭시게나아제 활성화 단백질 억제제
WO2009147187A1 (fr) 2008-06-05 2009-12-10 Glaxo Group Limited Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
KR101036913B1 (ko) * 2008-12-26 2011-05-25 주식회사 포스코 고로의 머드건과 노즐팁 사이의 틈새 메움용 장치 및 방법
EP2406255B1 (fr) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des pi3 kinases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (fr) 2009-03-17 2012-01-25 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107957A2 (fr) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Inhibition induite par arn interférence d'une expression génique (gata3) d'une protéine de liaison gata au moyen d'un acide nucléique interférent court
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
CN102439151A (zh) 2009-03-19 2012-05-02 默沙东公司 使用短干扰核酸（siNA）的RNA干扰介导的BTB和CNC同系物1，碱性亮氨酸拉链转录因子1（Bach1）基因表达的抑制
WO2010111471A2 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibition par interférence arn de l'expression du gène du signal transducteur et activateur de la transcription 1 (stat1) au moyen d'un acide nucléique interférent court (ansi)
WO2010111464A1 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi)
EP2411018A2 (fr) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
JO3025B1 (ar) 2009-04-30 2016-09-05 Glaxo Group Ltd الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
WO2011084316A2 (fr) 2009-12-16 2011-07-14 3M Innovative Properties Company Formulations et procédés pour le réglage de l'administration de particules d'une certaine taille dans un aérosol-doseur
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
ES2602972T3 (es) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2683716A1 (fr) 2011-03-11 2014-01-15 Glaxo Group Limited Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
RU2014126070A (ru) * 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний
BR112016003229A8 (pt) 2013-09-22 2020-02-04 Calitor Sciences Llc composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
WO2015148867A1 (fr) 2014-03-28 2015-10-01 Calitor Sciences, Llc Composés hétéroaryle substitués et procédés d'utilisation
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
FR3022142B1 (fr) 2014-06-16 2019-07-12 Universite Paul Sabatier - Toulouse Iii Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate
WO2017044434A1 (fr) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryle substitués et leurs méthodes d'utilisation
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
WO2019143874A1 (fr) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Composés d'aminopyrimidine substitués et procédés d'utilisation
EP4125919A1 (fr) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK289787A3 (en) * 1986-04-30 1998-06-03 Dainippon Pharmaceutical Co Substituted n-£(2-morpholinyl)alkyl|benzamide derivative, method of producing the same and a pharmaceutical composition on its base
JPS63264467A (ja) * 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
JPH01117882A (ja) 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
JPH04247074A (ja) * 1991-02-01 1992-09-03 Yoshitomi Pharmaceut Ind Ltd ４−モルホリノ安息香酸誘導体の製造法
DE69511086T2 (de) * 1994-05-18 2000-01-05 Nisshin Flour Milling Co Pyrimidinderivate
DE69527786T2 (de) 1994-05-18 2003-04-10 Nisshin Seifun Group Inc Diaminomethyliden-derivate
EP0827500B1 (fr) * 1995-05-23 2001-11-14 Janssen Pharmaceutica N.V. Derives de (2-morpholinylmethyl)benzamide
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
CA2329777A1 (fr) 1998-04-27 1999-11-04 Dashyant Dhanak Antagonistes du recepteur ccr-3
WO2000004003A1 (fr) 1998-07-14 2000-01-27 Smithkline Beecham Corporation Antagonistes du recepteur ccr-3
WO2000027800A1 (fr) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Antagonistes du recepteur ccr-3
WO2000027843A1 (fr) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Antagonistes du recepteur ccr3-3
WO2000027835A1 (fr) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Antagonistes du recepteur ccr-3
CN1163484C (zh) 1998-11-17 2004-08-25 霍夫曼-拉罗奇有限公司 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
WO2000031033A1 (fr) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Antagonistes du recepteur de piperidine ccr-3
ID29067A (id) 1998-11-20 2001-07-26 Hoffmann La Roche Turunan pirolidina-antagonis reseptor ccr-3
US6492364B1 (en) 1998-12-04 2002-12-10 Toray Industries, Inc. Triazolo and derivatives as chemokine inhibitors
WO2000035451A1 (fr) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
DE69926919D1 (de) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
CA2348923A1 (fr) 1998-12-18 2000-06-22 Dean A. Wacker N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6444686B1 (en) 1998-12-18 2002-09-03 Brsitol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035876A1 (fr) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocycles 2-substitues-4-azote utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
EP1156807A4 (fr) 1998-12-18 2002-04-03 Du Pont Pharm Co N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
WO2000041685A1 (fr) 1999-01-19 2000-07-20 Smithkline Beecham Corporation Antagonistes des recepteurs ccr-3
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000053172A1 (fr) 1999-03-08 2000-09-14 Smithkline Beecham Corporation Antagonistes du récepteur ccr-3
WO2000053600A1 (fr) 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Derives piperidiniques
CA2372887A1 (fr) * 1999-05-25 2000-11-30 Sepracor Inc. Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
KR20030031198A (ko) * 2000-09-29 2003-04-18 글락소 그룹 리미티드 염증 질환 치료용 모르폴린-아세트아미드 유도체

Also Published As

Publication number Publication date
WO2002026722A1 (fr) 2002-04-04
IL155093A0 (en) 2003-10-31
NO20031442L (no) 2003-05-26
JP5089846B2 (ja) 2012-12-05
NO20031442D0 (no) 2003-03-28
US20090163495A1 (en) 2009-06-25
AR035205A1 (es) 2004-05-05
ES2527688T3 (es) 2015-01-28
JP2004509952A (ja) 2004-04-02
KR20030031198A (ko) 2003-04-18
PL362711A1 (en) 2004-11-02
NZ525056A (en) 2004-11-26
BR0114323A (pt) 2003-07-01
EP1324990B1 (fr) 2014-10-29
CN1678594A (zh) 2005-10-05
CZ20031195A3 (cs) 2003-09-17
CA2423251A1 (fr) 2002-04-04
US7560548B2 (en) 2009-07-14
US20040058923A1 (en) 2004-03-25
US20050222147A1 (en) 2005-10-06
US7101882B2 (en) 2006-09-05
HUP0302302A2 (hu) 2003-12-29
US20060079525A1 (en) 2006-04-13
EP1324990A1 (fr) 2003-07-09
MXPA03002814A (es) 2003-10-14

Similar Documents

Publication Publication Date Title
AU2001290143A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
US7157457B2 (en) Compounds useful in the treatment of inflammatory diseases
EP1487828B1 (fr) Derives de morpholinyl-uree pour le traitement des maladies associees avec des procedes inflammatoires
EP1487455A1 (fr) Derives de morpholine substitues au niveau de la position 2 par un groupe arylalkyluree utilise en tant qu'antagonistes de ccr-3 dans le traitement d'etats inflammatoires
WO2003097618A1 (fr) Antagonistes du recepteur de morpholinylmethyluree ccr-3
ZA200302411B (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
WO2003099798A1 (fr) Morpholinylmethylure utilisee comme antagonistes du recepteur ccr-3
WO2003099287A1 (fr) Derives de morpholine-acetamide pour le traitement des maladies inflammatoires
WO2003082862A1 (fr) Derives de morpholine-acetamide anti-inflammatoires
WO2003082295A1 (fr) Derives de morpholine substitues en position 2 par un groupe heterocyclylalkylurea, destines a etre utilises en tant qu'antagonistes du recepteur ccr3 dans le traitement d'etats inflammatoires
EP1495020A1 (fr) Derives de n-(morpholin-2yl) methyle acetamide servant d'antagonistes de ccr-3 et utilises dans le traitement de maladies inflammatoires

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application